Overview

Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers

Status:
Active, not recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The study is designed as an open-label, randomized, prospective, multicenter, phase II study comparing pembrolizumab with methotrexate in elderly, frail or cisplatin-ineligible patients with squamous carcinoma of the head and neck (HNSCC)

Phase:

Phase 2

Details

Lead Sponsor:

AIO-Studien-gGmbH

Treatments:

Cisplatin
Methotrexate
Pembrolizumab